Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Bisaro Paul

DAMELIO FRANK A

MCCALLISTER MICHAEL B

PECK KRISTIN C

Zoetis Inc. faces a securities class action lawsuit covering January 14, 2025 through May 6, 2026, with CEO Kristin Peck and CFO Wetteny Joseph named as individual defendants. The lawsuit alleges they certified misleading statements about companion animal product performance while safety concerns and competitive losses mounted. Zoetis shares fell 21.5% to $87.31 on May 7, 2026 following corrective disclosures. The lead plaintiff deadline is set for July 27, 2026.

ZTS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Zoetis Inc. Securities Lawsuit - Contact SueWallSt

The veterinary lab automation market is experiencing robust growth, expanding from $1.26 billion in 2025 to $1.36 billion in 2026 at an 8.4% CAGR, with projections to reach $1.9 billion by 2030. Growth is driven by rising demand for rapid diagnostics, AI integration, companion animal care expansion, and robotic workflow adoption. North America leads the market while Asia-Pacific is positioned for rapid expansion.

Veterinary Lab Automation Global Market Report 2023 Now Available, Covers Asia-Pacific, North America, Europe, and More

A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false and misleading statements regarding its business operations between January 14, 2025 and May 6, 2026. The complaint alleges the company failed to disclose weakening veterinarian adoption of its Librela product due to FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors have until July 27, 2026 to apply as lead plaintiff.

Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors to Contact the Firm Before the July 27th Lead Plaintiff Deadline

Equity Analyst researching high-quality companies at Best Anchor Stocks and Invirtiendo en Calidad. 

Spanish account: @InvEnCalidad

Leandro

All value. No advice | Stock Newsletter https://t.co/9pEi00XIOe | all write-ups https://t.co/x5vF9ws8qv | HoldCo https://t.co/SMAxPD6QVx

Zoetis Inc (ZTS) Stock Price, Analysis & Trade Signals